Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3 December 3, 2024
Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections October 31, 2024
